News

For ocular herpetic infection, topical antiviral medication alone is not sufficient. Investigators found that systemic antiherpetic treatment is needed to prevent recurrence and graft failure after PK.

The company will add programs in diabetic macular edema and myopia as it completes pre-clinical studies.

BVS Sight Inc. was created through a partnership between Boomerang Ventures and Purdue Research Foundation.

The Alcon Children’s Vision Center is available for follow-up appointments and ongoing eye care, all free of charge for qualified students in need, from Pre-Kindergarten through Grade 12.

According to the company, the launch of the presbyopia phase 3 program is supported by positive clinical results that demonstrated durable efficacy and a favorable safety profile.

The researchers conducted a retrospective chart review of patients with typical exudative AMD that had been treated with anti-VEGF therapy injections.

NOV03 is being investigated to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction, and a PDUFA action date has been set for June 28.

Investigators conducted a cohort study to determine if there is a correlation between intake of nitrate and AMD progression based on previous suggestions that low nitrate levels in the diet may put patients at risk of AMD progression.

A team of researchers from the University of Wisconsin–Madison developed a way to grow organized clusters of cells, called organoids, that resemble the retina, the light-sensitive tissue at the back of the eye.

On this week's episode of the NeuroOp Guru video blog, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Thymectomy in Ocular Myasthenia Gravis, Yes or No?

Baumal replaces Federico Grossi, MD, PhD, who plans to remain at Apellis until Feb. 28 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy.

According to the company, its announcement represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients in need.

New educational campaign aims to educate individuals at risk for glaucoma and raise funding for glaucoma research.

The researchers reported that there was no significant difference in the AMD prevalence among the 3 study groups.

eSight is previewing its eSight Go, a wearable device that allows users to gain a level of independence.

Researchers at Washington University School of Medicine in St. Louis have found that proteins made by stem cells that regenerate the cornea may be new targets for treating and preventing such injuries.

According to the company, the NDA is based on data from the Phase 3 NEAR-1 and NEAR-2 clinical trials, involving more than 600 patients, which evaluated the efficacy and safety of CSF-1.

The technique provides model for studying genesis of age-related macular degeneration and other eye diseases.

Survey participants were asked to enumerate the signs, symptoms, and complaints, the preoperative visual acuities; complications requiring removal or exchange; and secondary interventions.

Derek Hodkey, president and CEO of Orbis International, discusses key achievements for the company and its Flying Eye Hospital in 2022 and offers his outlook for 2023.

Investigators test the efficacy of phentolamine alone and with low-dose pilocarpine.

According to the company, it is on track to initiate a Phase 2b trial in the first quarter of 2023, with topline data expected in the first quarter of 2024.

Researchers are looking for improved detection of disease in patients.

Not only is canaloplasty designed to treat the entire conventional outflow pathway, facilitating flow through the trabecular meshwork, Schlemm canal, and collector channels, but it does so without a stent and without removing tissue.

Janey Wiggs, MD, PhD, associate chief of Ophthalmology Clinical Research at Massachusetts Eye & Ear discusses genetics of glaucoma, providing an overview of what is known about genes and gene mutations that can cause or contribute to glaucoma.

According to a news release, Opus will advance preclinical development programs for BEST1– and RHO-related retinal diseases. The deal expands the company’s addressable patient population for its novel treatments for rare inherited retinal diseases.